Switzerland

Celonic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine

Lead Product(s): Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Intravacc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 29, 2020

Details:

Covid-19 vaccine is based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's prorietary Outer Membrane Vesicle (OMV) technology".

Neovii

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

TAU and Neovii Team Up to Develop Covid-19 Vaccine

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Tel Aviv University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 13, 2020

Details:

The deal provides Neovii with the exclusive right to develop and commercialise a platform technology created by Biotechnology professor Jonathan Gershoni of TAU’s School of Molecular Cell Biology, to rapidly identify epitope-based vaccines.

KD Pharma Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

KD Pharma Group & SLA Pharma Initiate Clinical Trial For COVID-19

Lead Product(s): Eicosapentaenoic Acid

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

EPAspire™ is shortly entering clinical trials as a promising candidate to treat patients with symptoms of the novel coronavirus infection. The MHRA in the UK has approved the trial.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

China approves use of Roche arthritis drug for some Covid-19 patients

Lead Product(s): Tocilizumab,Tanezumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2020

Details:

Chinese researchers recently registered a three-month clinical trial for Actemra that would recruit 188 coronavirus patients and take place from Feb 10 to May 10.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Celonic

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine

Neovii

TAU and Neovii Team Up to Develop Covid-19 Vaccine

KD Pharma Group

KD Pharma Group & SLA Pharma Initiate Clinical Trial For COVID-19

F. Hoffmann-La Roche

China approves use of Roche arthritis drug for some Covid-19 patients